VA's July Pharmaceutical Prime Vendor Contract Reaches $971.8M with McKesson Corporation

Contract Overview

Contract Amount: $971,836,194 ($971.8M)

Contractor: Mckesson Corporation

Awarding Agency: Department of Veterans Affairs

Start Date: 2024-07-01

End Date: 2024-07-31

Sector: Healthcare

Official Description: EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2024 JULY

Plain-Language Summary

Department of Veterans Affairs obligated $971.8 million to MCKESSON CORPORATION for work described as: EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2024 JULY Key points: 1. The Department of Veterans Affairs (VA) awarded a significant $971.8 million contract for pharmaceutical prime vendor services in July 2024. 2. McKesson Corporation is the sole awardee, indicating a potentially limited competitive landscape for this essential service. 3. The contract's substantial value highlights the critical need for reliable pharmaceutical supply chains within the VA. 4. Understanding the pricing mechanisms and potential for cost savings is crucial given the scale of this expenditure.

Value Assessment

Rating: good

The contract value of $971.8 million for a single month's pharmaceutical prime vendor services is substantial. Benchmarking against similar large-scale pharmaceutical distribution contracts is necessary to assess if this represents competitive pricing, though the nature of prime vendor agreements often involves complex pricing structures.

Cost Per Unit: N/A

Competition Analysis

Competition Level: sole-source

The award is identified as a sole-source contract. This limits direct price competition, suggesting that the VA may rely on established relationships, historical pricing, or specific performance requirements that favor a single vendor. Price discovery is likely driven by negotiation and contract terms rather than open market competition.

Taxpayer Impact: The sole-source nature necessitates careful negotiation to ensure taxpayer funds are used efficiently. Without open competition, the VA must ensure robust oversight to prevent overpricing and maintain value for money.

Public Impact

Ensures a steady supply of essential medications for veterans. Supports the VA's healthcare mission by providing critical pharmaceutical products. Impacts the broader pharmaceutical distribution market and its key players. Potential for price fluctuations based on market dynamics and contract terms.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

  • Sole-source award limits competitive pressure on pricing.
  • High contract value requires diligent oversight to ensure cost-effectiveness.
  • Dependence on a single vendor could pose supply chain risks if not managed proactively.

Positive Signals

  • Ensures critical pharmaceutical needs are met for veterans.
  • Leverages established vendor relationship for potentially streamlined operations.
  • Provides a predictable and reliable source of medications.

Sector Analysis

The pharmaceutical prime vendor sector is a critical component of the healthcare supply chain, ensuring the availability of medications. Spending in this sector is consistently high due to the essential nature of pharmaceuticals. Benchmarks for such large contracts are often proprietary or highly negotiated.

Small Business Impact

This contract is awarded to a large corporation, McKesson. There is no indication of small business participation in this specific award, which is common for large-scale prime vendor agreements that require extensive infrastructure and logistical capabilities.

Oversight & Accountability

The Department of Veterans Affairs is responsible for overseeing this contract. Given its sole-source nature and significant value, robust oversight mechanisms, including performance monitoring and regular price reviews, are essential to ensure accountability and value for taxpayer dollars.

Related Government Programs

  • Department of Veterans Affairs Contracting
  • Department of Veterans Affairs Programs

Risk Flags

  • Sole-source award limits competitive pressure.
  • High contract value necessitates stringent oversight.
  • Potential for supply chain disruption if vendor faces issues.
  • Dependence on vendor's pricing structure.

Tags

department-of-veterans-affairs, delivery-order, 100m-plus

Frequently Asked Questions

What is this federal contract paying for?

Department of Veterans Affairs awarded $971.8 million to MCKESSON CORPORATION. EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2024 JULY

Who is the contractor on this award?

The obligated recipient is MCKESSON CORPORATION.

Which agency awarded this contract?

Awarding agency: Department of Veterans Affairs (Department of Veterans Affairs).

What is the total obligated amount?

The obligated amount is $971.8 million.

What is the period of performance?

Start: 2024-07-01. End: 2024-07-31.

What specific performance metrics are in place to ensure McKesson Corporation is delivering pharmaceuticals efficiently and cost-effectively under this sole-source contract?

The contract likely includes specific performance standards related to delivery timeliness, order accuracy, inventory management, and potentially quality control of pharmaceutical products. The VA's oversight team would monitor these metrics, with potential penalties or incentives tied to performance. Regular reviews of pricing structures and market comparisons would also be part of ensuring cost-effectiveness, even without direct competition.

What is the VA's strategy for mitigating supply chain risks associated with relying on a single vendor for such a critical service?

The VA likely employs a multi-faceted risk mitigation strategy. This could include maintaining strong communication channels with McKesson, requiring robust business continuity and disaster recovery plans from the vendor, diversifying sources for critical drugs where possible, and potentially exploring alternative sourcing strategies for the future. Contingency planning and regular risk assessments are crucial.

How does the VA ensure that the pricing under this sole-source pharmaceutical prime vendor contract remains competitive and provides good value for taxpayer money?

While direct competition is absent, the VA likely uses several methods to ensure value. This includes negotiating favorable terms based on volume, referencing benchmark pricing from similar contracts or market indices, conducting regular price audits, and potentially incorporating price adjustment clauses tied to market fluctuations. Strong contract management and negotiation expertise are key.

More Contracts from Mckesson Corporation

View all Mckesson Corporation federal contracts →

Other Department of Veterans Affairs Contracts

View all Department of Veterans Affairs contracts →

Explore Related Government Spending